Pharma Focus Asia

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals

Tuesday, January 23, 2018

Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Ferring will be responsible for all costs related to the programs.

“Our OmniAb antibody discovery business is thriving as we continue to sign up new partners,” said John Higgins, Chief Executive Officer of Ligand. “There is significant demand for research tools to facilitate drug discovery, and our novel platform of transgenic animals, proprietary assays and intellectual property make our offering a very attractive package for licensing. We continue to invest in the platform and secure more deals that will drive Ligand’s future growth.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024